EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function

Matthew E Brown, Puchong Thirawatananond, Leeana D Peters, Elizabeth J Kern, Sonali Vijay, Lindsey K Sachs, Amanda L Posgai, Maigan A Brusko, Melanie R Shapiro, Clayton E Mathews, Rhonda Bacher, Todd M Brusko

Diabetologia · 2025-02 · 68 (2) · 397-418

DOI: 10.1007/s00125-024-06329-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, online erschienen am 05.12.2024. Verfasst von Matthew E Brown und 11 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, T-Lymphocytes, Regulatory, Antigens, Differentiation, T-Lymphocyte. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Diabetes Association, NIDDK NIH HHS, JDRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS/HYPOTHESIS: Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. There is an outstanding need to augment the durability and effectiveness of T cell targeting therapies by directly restraining proinflammatory T cell subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a novel strategy for preventing diabetes incidence in the NOD mouse model using a blocking monoclonal antibody targeting the type 1 diabetes risk-associated T cell co-stimulatory receptor, CD226. METHODS: Female NOD mice were treated with anti-CD226 at 7-8 weeks of age and then monitored for diabetes incidence and therapeutic mechanism of action. RESULTS: Compared with isotype-treated controls, anti-CD226-treated NOD mice showed reduced insulitis severity (0.84-fold, p=0.0002) at 12 weeks and decreased disease incidence (HR 0.41, p=0.015) at 30 weeks. Flow cytometric analysis performed 5 weeks post treatment demonstrated reduced proliferation of conventional CD4+ T cells (0.87-fold, p=0.030) and CD8+ (0.78-fold, p=0.0018) effector memory T cells in spleens of anti-CD226-treated mice. Phenotyping of pancreatic Tregs revealed increased CD25 expression (2.05-fold, p=0.0073) and signal transducer and activator of transcription 5 (STAT5) phosphorylation (1.39-fold, p=0.0007) following anti-CD226, with splenic Tregs displaying augmented suppression of CD4+ responder T cells (Tresps) (1.49-fold, p=0.0008, 1:2 Treg:Tresp) in vitro. Anti-CD226-treated mice exhibited reduced frequencies of islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-reactive CD8+ T cells in the pancreas, using both ex vivo tetramer staining (0.50-fold, p=0.0317) and single-cell T cell receptor sequencing (0.61-fold, p=0.022) approaches. 51Cr-release assays demonstrated reduced cell-mediated lysis of beta cells (0.61-fold, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1T-Lymphocytes, RegulatoryAntigens, Differentiation, T-LymphocyteAnimalsMice, Inbred NODMiceFemaleT Lineage-Specific Activation Antigen 1Antibodies, Monoclonal

Stichwörter der Autor:innen

CD226Disease preventionMonoclonal antibodyNOD mouseType 1 diabetes

Substanzen

Antigens, Differentiation, T-LymphocyteT Lineage-Specific Activation Antigen 1Antibodies, Monoclonal

Autor:innen und Institutionen

  • Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
  • Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL, USA. tbrusko@ufl.edu.
  • Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. tbrusko@ufl.edu.
  • Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA. tbrusko@ufl.edu.

Förderung

  • American Diabetes Association
  • NIDDK NIH HHS
  • JDRF
  • Diabetes Research Connection
  • NIGMS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences

Zitieren

APA

Brown, M. E., Thirawatananond, P., Peters, L. D., Kern, E. J., Vijay, S., Sachs, L. K., Posgai, A. L., Brusko, M. A., Shapiro, M. R., Mathews, C. E., Bacher, R., & Brusko, T. M. (2025). Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. Diabetologia, 68(2), 397-418. https://doi.org/10.1007/s00125-024-06329-8

Vancouver

Brown ME, Thirawatananond P, Peters LD, Kern EJ, Vijay S, Sachs LK, et al. Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. Diabetologia. 2025;68(2):397-418. doi:10.1007/s00125-024-06329-8

BibTeX
@article{Brown2025,
  author = {Brown, Matthew E and Thirawatananond, Puchong and Peters, Leeana D and Kern, Elizabeth J and Vijay, Sonali and Sachs, Lindsey K and Posgai, Amanda L and Brusko, Maigan A and Shapiro, Melanie R and Mathews, Clayton E and Bacher, Rhonda and Brusko, Todd M},
  title = {Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function},
  journal = {Diabetologia},
  year = {2025},
  volume = {68},
  number = {2},
  pages = {397--418},
  doi = {10.1007/s00125-024-06329-8}
}
Kostenlos starten →